<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897051</url>
  </required_header>
  <id_info>
    <org_study_id>CR310037</org_study_id>
    <nct_id>NCT01897051</nct_id>
  </id_info>
  <brief_title>Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients</brief_title>
  <acronym>RECOVER</acronym>
  <official_title>Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To reduce portal pressure, the only recommended medication is nonselective beta
      blocker(NSBB). However, NSBB has some limitation to apply clinically because of poor response
      rate and compliance.

      Recent literature has supported the role of bacterial translocation as a mediator of
      splanchnic vasodilatation and portal hypertension. This stimulates the release of
      pro-inflammatory cytokines and the activation of the vasodilator NO resulting in a more
      pronounced deterioration of the baseline hyperdynamic circulatory state. Selective gut
      decontamination with Rifaximin can induce inhibition of bacterial translocation and
      associated worsening of portal hypertension. The investigators hypothesized that Rifaximin
      plus NSBB could result in decrease of portal pressure in cirrhotic patients with esophageal
      varices.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic vein pressure gradient(HVPG)</measure>
    <time_frame>Change from baseline heptic vein pressure gradient at 6 weeks</time_frame>
    <description>After measurement of baseline HVPG, patients will be randomized to treatment group of Rifaximin + Propranolol or Propranolol + Placebo. And 6 weeks after treatment, follow-up measurement of HVPG will be performed to evaluate efficacy of two regimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurence of gastrointestinal bleeding</measure>
    <time_frame>upto 6 months after initiation of treatment</time_frame>
    <description>when gastrointestinal bleeding occurs, after initiation of treatment, endoscopy will be performed to evaluate status of bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin(normix®)+nonselective beta-blocker(Propranolol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nonselective beta-blocker(Propranolol) + Placebo(of Rifaximin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin + propranolol</intervention_name>
    <description>Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)
Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.
(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).
If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared.</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Normix</other_name>
    <other_name>Propranolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol + Placebo</intervention_name>
    <description>Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)
Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.
(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).
If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared.</description>
    <arm_group_label>Monotherapy</arm_group_label>
    <other_name>Non-selective beta-blocker</other_name>
    <other_name>Placebo of Rifaximin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis:diagnosed based on histology or unequivocal clinical, sonographic, and
             laboratory findings

          -  19≤age≤75

          -  Hepatic venous pressure gradient &gt; 12 mmHg

          -  Informed consent

        Exclusion Criteria:

          -  Shock status requiring vasopressor

          -  Active infection, for example Spontaneous bacterial peritonitis

          -  Acute renal failure patients of any cause

          -  Clinically relevant coronary artery disease(NYHA functional angina classification
             III/IV),congestive heart failure NYHA III/IV), clinically relevant cardiomyopathy,
             history of myocardial infarction in the past 12 months

          -  Poorly controlled hypertension (BP 150/100mmHg)

          -  Hepatocellular carcinoma

          -  History of another primary malignancy ≤ 3years

          -  Medical or psychological conditions that would not permit the subject to complete thte
             study or sign informed consent

          -  Pregnancy or lactation period

          -  Serum creatinine ≧ 6mg/dL

          -  Involvement in the conduct of other study within 30 days

          -  Known hypersensitivity to Rifaximin or propranolol

          -  Dysarrhythmia, inappropriate for study on investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moon Young Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moon Young Kim, M.D., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei University Wonhu College of Medicine Wonju Severance Christian Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moon Young Kim, MD,PhD</last_name>
    <phone>82-33-741-1225</phone>
    <email>drkimmy@yonsei.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Wonju Severance Cristian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Kangwon-do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moon Young Kim, MD,PhD</last_name>
      <phone>82-33-741-1225</phone>
      <email>drkimmy@yonsei.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Moon Young Kim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Moon Young Kim, MD., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med. 2003 Aug 5;139(3):186-93.</citation>
    <PMID>12899586</PMID>
  </reference>
  <reference>
    <citation>Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis DG. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009 May 1;29(9):992-9. doi: 10.1111/j.1365-2036.2009.03958.x. Epub 2009 Feb 7.</citation>
    <PMID>19210289</PMID>
  </reference>
  <reference>
    <citation>González A, Augustin S, Pérez M, Dot J, Saperas E, Tomasello A, Segarra A, Armengol JR, Malagelada JR, Esteban R, Guardia J, Genescà J. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study. Hepatology. 2006 Oct;44(4):806-12.</citation>
    <PMID>17006916</PMID>
  </reference>
  <reference>
    <citation>Ripoll C, Bañares R, Rincón D, Catalina MV, Lo Iacono O, Salcedo M, Clemente G, Núñez O, Matilla A, Molinero LM. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology. 2005 Oct;42(4):793-801.</citation>
    <PMID>16175621</PMID>
  </reference>
  <reference>
    <citation>Kumar M, Kumar A, Hissar S, Jain P, Rastogi A, Kumar D, Sakhuja P, Sarin SK. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int. 2008 May;28(5):690-8. doi: 10.1111/j.1478-3231.2008.01711.x.</citation>
    <PMID>18433395</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>April 19, 2015</last_update_submitted>
  <last_update_submitted_qc>April 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Moon Young Kim</investigator_full_name>
    <investigator_title>Associate Professor, Divistion of Gastroenterology and Hepatology, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Liver cirrhosis</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Hepatic Venous Pressure Gradient</keyword>
  <keyword>Rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

